ANDA 208549, held by Prinston Inc. Rivaroxaban.
As of Nov 13, 2026, ANDA 208549 (Rivaroxaban), held by Prinston Inc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 6, 2024 | Original application | Tentative approval | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Rivaroxaban10MG · tablet;oral | Rivaroxaban | None (tentative approval) |
| Rivaroxaban15MG · tablet;oral | Rivaroxaban | None (tentative approval) |
| Rivaroxaban20MG · tablet;oral | Rivaroxaban | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters